My Account Log in

1 option

Biosimilars in Europe / Arnold G Vulto, Steven Simoens, Isabelle Huys, editors.

DOAB Directory of Open Access Books Available online

View online
Format:
Book
Contributor:
Huys, Isabelle, editor.
Simoens, Steven, editor.
Vulto, Arnold G, editor.
Language:
English
Subjects (All):
Value analysis (Cost control).
Cost control.
Physical Description:
1 online resource (188 pages)
Place of Publication:
[Place of publication not identified] : MDPI - Multidisciplinary Digital Publishing Institute, 2023.
Language Note:
In English.
Summary:
This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
Contents:
About the Editors vii
Emerging Insights into European Markets of Biologics, Including Biosimilars 1
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019 5
Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria 21
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study 31
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany 39
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain 59
The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition? 75
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices 81
Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review 109
Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities 127
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars 143
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations 157.
Notes:
Description based on publisher supplied metadata and other sources.
ISBN:
3-0365-6574-4

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account